Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Publication Date
2021-12-31Journal Title
Cells
ISSN
2073-4409
Publisher
MDPI AG
Volume
11
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Lussier, T., Schoebe, N., & Mai, S. (2021). Risk Stratification and Treatment in Smoldering Multiple Myeloma.. Cells, 11 (1) https://doi.org/10.3390/cells11010130
Abstract
Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. Since its identification in 1980, risk stratification models have been developed using two main stratification methods: clinical measurement-based and genetics-based. Clinical measurement models can be subdivided in three types: baseline measurements (performed at diagnosis), evolving measurements (performed over time during follow-up appointments), and imaging (for example, magnetic resonance imaging). Genetic approaches include gene expression profiling, DNA/RNA sequencing, and cytogenetics. It is important to accurately distinguish patients with indolent disease from those with aggressive disease, as clinical trials have shown that patients designated as "high-risk of progression" have improved outcomes when treated early. The risk stratification models, and clinical trials are discussed in this review.
Keywords
smoldering multiple myeloma, risk stratification, treatment
Identifiers
External DOI: https://doi.org/10.3390/cells11010130
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332480
Rights
Licence:
https://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.